Literature DB >> 18265979

Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.

Stephanie S Tseng-Rogenski1, Mohamed S Arredouani, Yilin C Neeley, Bin Lu, Arul M Chinnaiyan, Martin G Sanda.   

Abstract

A pivotal obstacle to cancer immunotherapy is peripheral T cell tolerance to tumor-associated antigens (TAAs). Tolerance induction among mature T cells in the periphery operates through a variety of mechanisms, including anergy and apoptosis. Although Fas-FasL-mediated apoptosis is a well-defined tolerance inducing mechanism, direct evidence of its interference with TAA-specific immunity in vivo is still lacking. In this report, we used the TRAMP mouse, which expresses SV40 large T antigen (Tag) preferentially in the prostate and develops prostate tumors, as a model system to address the role of Fas-mediated apoptosis in regulating peripheral T cell tolerance. Using RT-PCR and tetramer staining to quantify TAA-specific TCR-expressing cytolytic T lymphocytes (CTLs), we have shown the presence of TAA-specific CTLs at higher levels in TRAMP mice than in syngeneic C57Bl/6 mice. Tag-specific immunization led to the expansion of Tag-specific CTLs in C57Bl/6 mice, and to their elimination in TRAMP mice. Interestingly, in TRAMP mice with deficient Fas (Hybrid TRAMP-lpr/lpr), Tag-specific CTL elimination in response to Tag immunization did not take place. The results of cytolytic-function assays were consistent with induction and elimination patterns of TAA-specific CTLs and those of RT-PCR and tetramer staining. In conclusion, our data show that Fas-mediated TAA-specific CTL apoptosis contributes to T cell tolerance and suggest that such tolerance could be potentiated following TAA-specific immunization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18265979     DOI: 10.1007/s00262-008-0471-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  4 in total

1.  Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.

Authors:  Mohamed S Arredouani; Stephanie S Tseng-Rogenski; Brent K Hollenbeck; June Escara-Wilke; Karen R Leander; Deborah Defeo-Jones; Clara Hwang; Martin G Sanda
Journal:  Prostate       Date:  2010-06-15       Impact factor: 4.104

Review 2.  Drug discovery in prostate cancer mouse models.

Authors:  Kenneth C Valkenburg; Kenneth J Pienta
Journal:  Expert Opin Drug Discov       Date:  2015-06-01       Impact factor: 6.098

3.  In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.

Authors:  Elizabeth J Akins; Miranda L Moore; Shuai Tang; Mark C Willingham; Janet A Tooze; Purnima Dubey
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

4.  TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.

Authors:  Moniek A de Witte; Gavin M Bendle; Marly D van den Boom; Miriam Coccoris; Todd D Schell; Satvir S Tevethia; Harm van Tinteren; Elly M Mesman; Ji-Ying Song; Ton N M Schumacher
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.